Effect of Xingnaojing Injection Combined with Butylphthalide Soft Capsules in Patients with Acute Cerebral Infarction and its Influence on Hemorheological and Peripheral Blood IL-23 and MIP-1α Levels
Objective:To investigate the effect of Xingnaojing Injection combined with Butylphthalide Soft Capsules in patients with acute cerebral infarction(ACI),and its influence on hemorheological and peripheral blood interleukin-23(IL-23)and macrophage inflammatory protein-l alpha(MIP-1 α)levels.Methods:A total of 106 patients with ACI admitted to the first affiliated hospital of henan university of science and technology from July 2018 to July 2022 were selected,and divided into two groups by random number table method,with 53 patients in each group.Patients in the control group took Butylphthalide Soft Capsules orally,and patients in the observation group were treated with Xingnaojing Injection on the basis of the treatment of Butylphthalide Soft Capsules.The two groups were compared in terms of clinical efficacy,the National Institutes of Health Stroke Scale(NIHSS)scores,hemorheological indicators,peripheral blood IL-23 and MIP-1 α levels before and after treatment.Results:After treatment,the total effective rate of the observation group was 94.34％,which was higher than the control group's 79.25％(P＜0.05);the NIHSS scores of both groups were significantly lower than before intervention,and the observation group was lower than the control group,with statistical significance(P＜0.05);the plasma viscosity(PV),fibrinogen(FIB),and hematocrit(HCT)of the two groups were significantly reduced compared to before intervention,and the observation group was lower than the control group,with statistical significance(P＜0.05);the levels of IL-23 and MIP-1 α in both groups were significantly reduced compared to before intervention,and the observation group was lower than the control group,with statistical significance(P＜0.05).Conclusion:The combination of Xingnaojing Injection and Butylphthalein Soft Capsule has a good therapeutic effect on ACI patients.It can significantly reduce NIHSS score,regulate hemorheological indicators,and lower peripheral blood IL-23 and MIP-1 α levels.
万方数据
维普
